Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emil Lou

Showing results (141-150 of 184) with videos related to

Pageof 19
Sort By:
Iscience|October 7, 2025
SARS-CoV-2 infection drives local inflammation of the intestinal epithelium in immunocompromised patients with cancerEmil Lou, Christine Luo, Katherine Ladner, et al.
JCO Oncology Advances|May 7, 2025
Multiomic Characterization of <i>RCC1</i> and <i>RCC2</i> Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer OutcomesMisako Nagasaka, Brian Warnecke, Sai-Hong Ignatius Ou, et al.
BMC Cancer|March 13, 2025
Identifying distinct prognostic and predictive contributions of tumor epithelium versus tumor microenvironment in colorectal cancerMingli Yang, Michael V Nebozhyn, Michael J Schell, et al.
NPJ Precision Oncology|February 26, 2026
Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancerIbrahim Halil Sahin, Joanne Xiu, Yasmine Baca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2024
Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene AlterationsMoh'd M Khushman, Michael D Toboni, Joanne Xiu, et al.
Annals of Surgery|October 28, 2025
SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment of Localized Pancreatic Cancer : A Multicenter, Retrospective Cohort StudyJulia Button, Elishama Kanu, Ethan Agritelley, et al.
Frontiers in Oncology|May 11, 2023
<i>ERBB</i> family fusions are recurrent and actionable oncogenic targets across cancer typesLaura Schubert, Andrew Elliott, Anh T Le, et al.
Human Pathology|July 19, 2022
Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreasAnastasios Gkountakos, Andrea Mafficini, Emil Lou, et al.
Cancer Research Communications|January 28, 2025
Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic TargetingJohn R Lozada, Andrew Elliott, Mark G Evans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2022
Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic AdenocarcinomaPhilip A Philip, Ibrahim Azar, Joanne Xiu, et al.
Pageof 19

Showing results (141-150 of 184) with videos related to

Sort By:
Pageof 19
Iscience|October 7, 2025
SARS-CoV-2 infection drives local inflammation of the intestinal epithelium in immunocompromised patients with cancerEmil Lou, Christine Luo, Katherine Ladner, et al.
JCO Oncology Advances|May 7, 2025
Multiomic Characterization of <i>RCC1</i> and <i>RCC2</i> Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer OutcomesMisako Nagasaka, Brian Warnecke, Sai-Hong Ignatius Ou, et al.
BMC Cancer|March 13, 2025
Identifying distinct prognostic and predictive contributions of tumor epithelium versus tumor microenvironment in colorectal cancerMingli Yang, Michael V Nebozhyn, Michael J Schell, et al.
NPJ Precision Oncology|February 26, 2026
Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancerIbrahim Halil Sahin, Joanne Xiu, Yasmine Baca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2024
Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene AlterationsMoh'd M Khushman, Michael D Toboni, Joanne Xiu, et al.
Annals of Surgery|October 28, 2025
SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment of Localized Pancreatic Cancer : A Multicenter, Retrospective Cohort StudyJulia Button, Elishama Kanu, Ethan Agritelley, et al.
Frontiers in Oncology|May 11, 2023
<i>ERBB</i> family fusions are recurrent and actionable oncogenic targets across cancer typesLaura Schubert, Andrew Elliott, Anh T Le, et al.
Human Pathology|July 19, 2022
Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreasAnastasios Gkountakos, Andrea Mafficini, Emil Lou, et al.
Cancer Research Communications|January 28, 2025
Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic TargetingJohn R Lozada, Andrew Elliott, Mark G Evans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2022
Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic AdenocarcinomaPhilip A Philip, Ibrahim Azar, Joanne Xiu, et al.
Pageof 19